Cynthia A Toth1, Vincent Tai2, Maxwell Pistilli3, Stephanie J Chiu2, Katrina P Winter2, Ebenezer Daniel3, Juan E Grunwald3, Glenn J Jaffe2, Daniel F Martin4, Gui-Shuang Ying5, Sina Farsiu5, Maureen G Maguire3. 1. Department of Ophthalmology, Duke University, Durham, North Carolina; Department of Biomedical Engineering, Duke University, Durham, North Carolina. Electronic address: cynthia.toth@duke.edu. 2. Department of Ophthalmology, Duke University, Durham, North Carolina. 3. Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. 5. Department of Biomedical Engineering, Duke University, Durham, North Carolina.
Abstract
PURPOSE: Macular atrophy and scar increase in prevalence during treatment for neovascular age-related macular degeneration and are associated with poor visual acuity. We sought to identify the distribution of spectral-domain OCT (SD-OCT)-determined features and subretinal lesion thicknesses at sites of macular scar or atrophy after 2 years of treatment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Cross-sectional analysis. PARTICIPANTS: CATT participants with SD-OCT, color photographic (CP) and fluorescein angiogram (FA; CP/FA) images at year 2. METHODS: Sixty-eight study eyes at year 2 in CATT were selected based on image quality and CP/FA-determined predominant presence of the following: geographic atrophy (GA, n = 25), non-GA (NGA, n = 44), fibrotic scar (FS, n = 26), or non-FS (NFS, n = 7). The CP/FA components were delineated by CP/FA readers; SD-OCT morphologic features and thicknesses were delineated by OCT readers. Using custom software and graphic user interfaces, images were registered, overlaying features and components per pixel; differences were analyzed across groups. MAIN OUTCOME MEASURES: OCT features, CP/FA components, and retinal and subretinal lesion thicknesses at each pixel of regional overlays. RESULTS: SD-OCT assessment of registered areas of pathology revealed the following: (1) retinal pigment epithelium atrophy (with or without residual lesion material) covered 75% of pixels designated as GA, 22% of NGA, 24% of NFS, and 46% of FS (P < 0.001). (2) Photoreceptor layer thinning covered 85% of GA, 42% of NGA, 33% of NFS, and 59% of FS (P < 0.001). (3) Subretinal lesion features covered 31% of GA, 42% of NGA, 85% of NFS, and 92% of FS (P < 0.001). Mean thickness of the subretinal lesion complex (measured in microns ± standard deviation) differed among GA (48±25 μm), NGA (61±35 μm), NFS (83±17 μm), and FS (151±74 μm) (P < 0.001). In eyes with GA, the thickness was greater in areas with residual lesion (51.4±27 μm) than in those without (27.2±9 μm). CONCLUSIONS: Retinal pigment epithelium atrophy and photoreceptor layer thinning are common not only in areas of macular atrophy but also in areas of FS. Photoreceptor loss extends beyond the areas of clinically apparent atrophy and FS. Subretinal lesion components were common in areas of scar, but they were also present in nearly one-third or more of areas of macular atrophy.
PURPOSE:Macular atrophy and scar increase in prevalence during treatment for neovascular age-related macular degeneration and are associated with poor visual acuity. We sought to identify the distribution of spectral-domain OCT (SD-OCT)-determined features and subretinal lesion thicknesses at sites of macular scar or atrophy after 2 years of treatment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Cross-sectional analysis. PARTICIPANTS: CATT participants with SD-OCT, color photographic (CP) and fluorescein angiogram (FA; CP/FA) images at year 2. METHODS: Sixty-eight study eyes at year 2 in CATT were selected based on image quality and CP/FA-determined predominant presence of the following: geographic atrophy (GA, n = 25), non-GA (NGA, n = 44), fibrotic scar (FS, n = 26), or non-FS (NFS, n = 7). The CP/FA components were delineated by CP/FA readers; SD-OCT morphologic features and thicknesses were delineated by OCT readers. Using custom software and graphic user interfaces, images were registered, overlaying features and components per pixel; differences were analyzed across groups. MAIN OUTCOME MEASURES: OCT features, CP/FA components, and retinal and subretinal lesion thicknesses at each pixel of regional overlays. RESULTS: SD-OCT assessment of registered areas of pathology revealed the following: (1) retinal pigment epithelium atrophy (with or without residual lesion material) covered 75% of pixels designated as GA, 22% of NGA, 24% of NFS, and 46% of FS (P < 0.001). (2) Photoreceptor layer thinning covered 85% of GA, 42% of NGA, 33% of NFS, and 59% of FS (P < 0.001). (3) Subretinal lesion features covered 31% of GA, 42% of NGA, 85% of NFS, and 92% of FS (P < 0.001). Mean thickness of the subretinal lesion complex (measured in microns ± standard deviation) differed among GA (48±25 μm), NGA (61±35 μm), NFS (83±17 μm), and FS (151±74 μm) (P < 0.001). In eyes with GA, the thickness was greater in areas with residual lesion (51.4±27 μm) than in those without (27.2±9 μm). CONCLUSIONS:Retinal pigment epithelium atrophy and photoreceptor layer thinning are common not only in areas of macular atrophy but also in areas of FS. Photoreceptor loss extends beyond the areas of clinically apparent atrophy and FS. Subretinal lesion components were common in areas of scar, but they were also present in nearly one-third or more of areas of macular atrophy.
Authors: W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang Journal: Eye (Lond) Date: 2015-10 Impact factor: 3.775
Authors: Hrvoje Bogunovic; Sebastian M Waldstein; Thomas Schlegl; Georg Langs; Amir Sadeghipour; Xuhui Liu; Bianca S Gerendas; Aaron Osborne; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2017-06-01 Impact factor: 4.799
Authors: Ebenezer Daniel; Wei Pan; Gui-Shuang Ying; Benjamin J Kim; Juan E Grunwald; Frederick L Ferris; Glenn J Jaffe; Cynthia A Toth; Daniel F Martin; Stuart L Fine; Maureen G Maguire Journal: Ophthalmology Date: 2018-02-14 Impact factor: 12.079
Authors: Sophie Klimscha; Sebastian M Waldstein; Thomas Schlegl; Hrvoje Bogunovic; Amir Sadeghipour; Ana-Maria Philip; Dominika Podkowinski; Eleonore Pablik; Li Zhang; Michael D Abramoff; Milan Sonka; Bianca S Gerendas; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2017-08-01 Impact factor: 4.799
Authors: Gui-shuang Ying; Benjamin J Kim; Maureen G Maguire; Jiayan Huang; Ebenezer Daniel; Glenn J Jaffe; Juan E Grunwald; Kevin J Blinder; Christina J Flaxel; Firas Rahhal; Carl Regillo; Daniel F Martin Journal: JAMA Ophthalmol Date: 2014-08 Impact factor: 7.389
Authors: Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin Journal: Ophthalmology Date: 2013-09-29 Impact factor: 12.079
Authors: Glenn J Jaffe; Daniel F Martin; Cynthia A Toth; Ebenezer Daniel; Maureen G Maguire; Gui-Shuang Ying; Juan E Grunwald; Jiayan Huang Journal: Ophthalmology Date: 2013-05-01 Impact factor: 12.079
Authors: Srinivas R Sadda; Robyn Guymer; Frank G Holz; Steffen Schmitz-Valckenberg; Christine A Curcio; Alan C Bird; Barbara A Blodi; Ferdinando Bottoni; Usha Chakravarthy; Emily Y Chew; Karl Csaky; Ronald P Danis; Monika Fleckenstein; K Bailey Freund; Juan Grunwald; Carel B Hoyng; Glenn J Jaffe; Sandra Liakopoulos; Jordi M Monés; Daniel Pauleikhoff; Philip J Rosenfeld; David Sarraf; Richard F Spaide; Ramin Tadayoni; Adnan Tufail; Sebastian Wolf; Giovanni Staurenghi Journal: Ophthalmology Date: 2017-11-02 Impact factor: 12.079
Authors: Yan Gong; Yohei Tomita; Matthew L Edin; Anli Ren; Minji Ko; Jay Yang; Edward Bull; Darryl C Zeldin; Ann Hellström; Zhongjie Fu; Lois E H Smith Journal: Metabolism Date: 2022-07-19 Impact factor: 13.934
Authors: Ebenezer Daniel; Maureen G Maguire; Juan E Grunwald; Cynthia A Toth; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Maximilian Pfau; Leon von der Emde; Luis de Sisternes; Joelle A Hallak; Theodore Leng; Steffen Schmitz-Valckenberg; Frank G Holz; Monika Fleckenstein; Daniel L Rubin Journal: JAMA Ophthalmol Date: 2020-10-01 Impact factor: 7.389
Authors: Avni P Finn; Maxwell Pistilli; Vincent Tai; Ebenezer Daniel; Gui-Shuang Ying; Maureen G Maguire; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Cynthia A Toth Journal: Am J Ophthalmol Date: 2020-11-19 Impact factor: 5.258